Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274375 | 1.00 | RIPK1 (0.50) | RIPK1HTR1APARP1SLC6A7AOC3 | |
| SCHEMBL30173617 | 0.91 | RIPK1 (0.50) | RIPK1HTR1A | |
| SCHEMBL25240594 | 0.91 | RIPK1 (0.50) | RIPK1HTR1A | |
| SCHEMBL24055262 | 0.91 | RIPK1 (0.50) | RIPK1HTR1A | |
| SCHEMBL30173664 | 0.87 | RIPK1 (0.41) | RIPK1HTR1APARP1SLC6A7AOC3 | |
| SCHEMBL25274823 | 0.87 | RIPK1 (0.41) | RIPK1HTR1APARP1SLC6A7AOC3 | |
| SCHEMBL24056629 | 0.87 | RIPK1 (0.41) | RIPK1HTR1APARP1SLC6A7AOC3 | |
| SCHEMBL24054359 | 0.86 | RIPK1 (0.49) | RIPK1PARP1SLC6A7 | |
| SCHEMBL30166395 | 0.86 | RIPK1 (0.49) | RIPK1PARP1SLC6A7 | |
| SCHEMBL30166456 | 0.84 | RIPK1 (0.46) | RIPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612388-B2 | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | Sironax Ltd. (KY) | 2026-04-28 | — | — | US | disclosed |
| CN-115697972-B | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide urea | 维泰瑞隆有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230192662-A1 | Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas | Sironax Ltd. (KY) | 2023-06-22 | — | — | US | disclosed |
| US-20230192662-A1 | Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas | Sironax Ltd. (KY) | 2023-06-22 | — | — | US | disclosed |
| CN-115697972-A | Receptor-interacting protein 1 inhibitors comprising piperazine heterocyclic amide ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021233394-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS INCLUDING PIPERAZINE HETEROCYCLIC AMIDE UREAS | Sironax Ltd. (KY) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192662-A1 | Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885HTR1A 1701/4885PARP1 752/4885 |
| US-12612388-B2 | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | NCOR1, NCOR2, SUCNR1 | RIPK1 4/4885HTR1A 1738/4885PARP1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.